The first patient has been dosed in a Phase 1/2 clinical study of VTx-002, an experimental therapy for amyotrophic lateral sclerosis.

Origami is collaborating with Ipsen to develop molecules designed to remove or correct abnormal proteins in neurodegenerative diseases.

A bipartisan team of U.S. lawmakers has reintroduced the ALS Better Care Act, aimed at improving access to quality medical ...

Scientists developed a technique to grow cells that control voluntary movement, a discovery that could aid ALS and spinal ...

Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166 ...

Some weights weren't getting any use until columnist Dagmar Munn applied one of her "imaginary rules" toward a lesson in ...

A viral infection can trigger a neurological disease similar to amyotrophic lateral sclerosis (ALS) in mice with a specific ...

A new survey suggests many people with ALS would value even modest slowing of ALS progression as a treatment goal.

Coya Therapeutics raised $11.1 million to support manufacturing scale-up for its experimental ALS therapy, COYA 302.

Amyotrophic lateral sclerosis (ALS) is a severe neurodegenerative disease characterized by the progressive loss of motor neurons, nerve cells that control the voluntary muscles. This leads to overall ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that can be classified into different types based on factors like genetics, a patient’s family history, and the ...

Being diagnosed with amyotrophic lateral sclerosis (ALS) is life-changing. Navigating the impact it has on physical well-being can, not surprisingly, also affect mental health. While some people may ...